Introduction
Progressive neurodegenerative processes in laboratory models of Parkinson’s disease (PD) and Alzheimer’s disease (AD) converge on synaptic failure, proteostasis disruption, neuroinflammation, and selective neuronal vulnerability. Canonical features include dopaminergic circuit deterioration with α-synuclein aggregation in PD, and amyloid-β (Aβ) plaque deposition with tau pathology in AD. Conventional research tools often interrogate single pathways in isolation, which can obscure the multifactorial crosstalk among glial immunity, neuronal metabolism, and vesicle-mediated signaling. This has stimulated interest in nanoscale carriers that naturally shuttle multimodal molecular payloads across compartments in experimental systems.
Mesenchymal stem/stromal cells (MSCs) secrete extracellular vesicles (EVs), including exosomes (~30–150 nm), enriched in proteins, lipids, and nucleic acids (for example, microRNAs) that can influence recipient-cell phenotypes in vitro and in vivo. MSC-derived exosomes appear to interface with neuroinflammatory signaling, proteostatic clearance, and plasticity programs in preclinical preparations. Here, we synthesize mechanistic themes from these investigations while emphasizing cautious, hypothesis-driven interpretation and the need for rigorous, standardized laboratory protocols.
Vesicle Biogenesis and Molecular Cargo: A Multimodal Signaling Toolkit
Exosomes originate from endosomal multivesicular bodies and are released upon fusion with the plasma membrane. MSC-derived exosomes carry chemokines, cytokines, enzymes, growth factors, lipids, and regulatory RNAs (for example, miR-143, miR-21, and engineered miR-188-3p) that can modulate gene expression networks in recipient neural and glial cells. Proteomic and enzymatic analyses indicate the presence of Aβ-degrading enzymes such as neprilysin, suggesting a potential route for extracellular proteostasis support in AD models. Because cargo composition depends on MSC tissue source, culture conditions, and priming cues, exosome preparations from bone marrow, adipose tissue, umbilical cord, placenta, or dental pulp may display distinct surface markers and bioactivities, underscoring the importance of source-matched controls and reproducible isolation schemes.
Interfaces with Neuroinflammation and Innate Immunity
Multiple preclinical reports indicate that MSC exosomes can attenuate pro-inflammatory signaling cascades implicated in neurodegeneration. Proposed mechanisms include miRNA-mediated repression of NF-κB pathway components, modulation of JAK/STAT tone in glia, and rebalancing of microglial phenotypes toward homeostatic states. In traumatic and toxin-based brain injury paradigms, exosome exposure has been associated with reduced cytokine levels and enhanced resolution markers, aligning with decreased leukocyte infiltration and improved tissue integrity. These observations remain model- and preparation-dependent, motivating quantitative, cell-type-resolved readouts (single-cell transcriptomics, cytokine multiplexing, and spatial proteomics) to map causal nodes.
Proteostasis and Autophagy: Aβ and α-Synuclein Handling
In AD-relevant systems, MSCs and their exosomes have been reported to increase autophagic flux markers and lower extracellular Aβ burden, potentially via cargo-borne neprilysin and miRNAs that upregulate lysosomal and macroautophagic pathways. In PD-oriented models, exosomes have been observed to influence α-synuclein homeostasis by suppressing upstream components of the aggregation pathway or by enhancing clearance mechanisms. Because EVs themselves can transport misfolded proteins in other contexts, careful characterization of bidirectional flux (cargo in, cargo out) is essential to ensure that net effects reflect enhanced degradation rather than redistribution.
Neuroregeneration and Circuit Plasticity in Experimental Models
MSCs secrete a “secretome” rich in trophic factors (for example, BDNF-like signaling surrogates) that, via exosomes, may support axonal growth, synaptogenesis, and neurogenesis in rodent preparations. Experimental readouts include increased dendritic complexity, enhanced long-term potentiation, and improved performance on behavioral assays that index learning or motor coordination. These findings suggest that EV cargo can recalibrate activity-dependent plasticity programs. Parsing direct neuronal effects from glia-mediated, non-cell-autonomous mechanisms will benefit from co-culture systems, chemogenetic dissection, and circuit-level imaging.
Biodistribution, Barrier Transit, and Delivery Variables
Several studies report that MSCs and their EVs can traverse the blood–brain barrier (BBB) in model organisms and distribute to olfactory bulb, hippocampus, striatum, cerebellum, brainstem, amygdala, and spinal cord. Exosome biodistribution depends on vesicle size, surface ligands (for example, integrins, tetraspanins), and route of experimental delivery (including localized or noninvasive strategies in animals). Long half-life and low apparent immunogenicity have been described in preclinical settings; nonetheless, EV pharmacokinetics can vary widely across isolation methods and species, necessitating standardized nanoparticle tracking, fluorescent/NIR labeling, and quantitative mass spectrometry to correlate exposure with molecular and behavioral endpoints.
Source Heterogeneity and Standardization Challenges
Although “MSC” is a shared designation, tissue-of-origin differences yield distinct antigen profiles and secretory landscapes. Isolation, culture density, oxygen tension, priming with inflammatory cues, and passage number all shape exosome composition. Discrepancies across laboratories can therefore reflect upstream culture variance rather than true biological divergence. Adoption of minimal information standards for EV studies (for example, MISEV-style reporting), orthogonal purification (size-exclusion plus density gradients), and batch-to-batch reference materials will improve reproducibility and meta-analytic interpretability.
Engineered Exosomes: Toward Mechanism-Focused Probes
Genetic or chemical engineering of MSCs can bias exosome cargo to interrogate specific hypotheses. Examples include overexpressing neprilysin to augment Aβ degradation in AD models or loading miR-188-3p to tune PD-relevant pathways. Ligand display on exosome membranes may enhance tropism to neuronal subtypes or inflamed vasculature, enabling targeted delivery in vivo. Such “designer EVs” function as mechanistic tools to test causal roles of individual molecules within the broader secretome milieu, provided off-target effects and cargo stoichiometries are carefully quantified.
Behavioral and Systems-Level Readouts in PD and AD Paradigms
In toxin-based and transgenic PD models, MSC-derived exosomes have been associated with improved motor behaviors and dampened α-synuclein pathway activity, whereas in AD-oriented rodent and cellular systems, investigators report enhanced autophagy, reduced Aβ levels, and improved mnemonic performance. Because behavioral gains can arise from diverse upstream changes (neuroinflammation, synaptic scaling, metabolic support), future studies should integrate multi-omic endpoints with circuit mapping to align molecular shifts with network-level function.
Outlook: Integrative Experimental Frameworks
The preclinical landscape suggests that MSC-derived exosomes constitute adaptable tools for probing neuroimmune crosstalk, proteostasis, and plasticity in neurodegeneration models. Priority areas include: (i) harmonized EV characterization pipelines; (ii) cell-type-specific targeting to resolve recipient-cell contributions; (iii) longitudinal biodistribution and PK/PD modeling; and (iv) head-to-head comparisons of MSC sources under identical conditions. Such frameworks will sharpen mechanistic inferences and clarify when exosome-mediated effects arise from enzymatic cargo, regulatory RNAs, or membrane ligand–receptor interactions.
Conclusion
MSC-derived exosomes provide a modular, multimolecular signaling platform that can interface with inflammation, proteostasis, and plasticity pathways central to PD and AD pathobiology in experimental systems. Evidence across in vitro and in vivo models points to roles in dampening pro-inflammatory cascades, enhancing autophagic clearance of pathogenic proteins, and supporting neural network function. Given substantial heterogeneity in MSC sources, EV isolation methods, and delivery paradigms, continued work emphasizing standardization, quantitative cargo profiling, and circuit-resolved analyses is essential. Overall, these vesicles remain promising research tools to dissect complex neurodegenerative mechanisms, with further laboratory investigation warranted.
References
- Park, H. J., Lee, P. H., Bang, O. Y., Lee, G., & Ahn, Y. H. (2008). Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease. Journal of neurochemistry, 107(1), 141-151.
- Li, Q., Wang, Z., Xing, H., Wang, Y., & Guo, Y. (2021). Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease. Molecular Therapy-Nucleic Acids, 23, 1334-1344.
- Kim, H. J., Cho, K. R., Jang, H., Lee, N. K., Jung, Y. H., Kim, J. P., … & Na, D. L. (2021). Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: A phase I clinical trial. Alzheimer’s research & therapy, 13(1), 1-11.
- Fričová, D., Korchak, J. A., & Zubair, A. C. (2020). Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson’s disease. NPJ Regenerative medicine, 5(1), 1-10.
- Mendes Filho, D., dC Ribeiro, P., Oliveira, L. F., de Paula, D. R., Capuano, V., de Assunção, T. S., & da Silva, V. J. (2018). Therapy with mesenchymal stem cells in Parkinson disease: history and perspectives. The Neurologist, 23(4), 141-147.
- d’Angelo, M., Cimini, A., & Castelli, V. (2020). Insights into the effects of mesenchymal stem cell-derived secretome in Parkinson’s Disease. International Journal of Molecular Sciences, 21(15), 5241.
- Chen, Y. A., Lu, C. H., Ke, C. C., & Liu, R. S. (2021). Mesenchymal stem cell-derived extracellular vesicle-based therapy for Alzheimer’s disease: progress and opportunity. Membranes, 11(10), 796.
- Jeong, H., Kim, O. J., Oh, S. H., Lee, S., Reum Lee, H. A., Lee, K. O., … & Kim, N. K. (2021). Extracellular Vesicles Released from Neprilysin Gene-Modified Human Umbilical Cord-Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer’s Disease Animal Model. Stem cells international, 2021.
- Andrzejewska, A., Dabrowska, S., Lukomska, B., & Janowski, M. (2021). Mesenchymal stem cells for neurological disorders. Advanced Science, 8(7), 2002944.
- Boika, A., Aleinikava, N., Chyzhyk, V., Zafranskaya, M., Nizheharodava, D., & Ponomarev, V. (2020). Mesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period. Surgical Neurology International, 11.
- Salem, A. M., Ahmed, H. H., Atta, H. M., Ghazy, M. A., & Aglan, H. A. (2014). Potential of bone marrow mesenchymal stem cells in management of Alzheimer’s disease in female rats. Cell biology international, 38(12), 1367-1383.
- Shin, J. Y., Park, H. J., Kim, H. N., Oh, S. H., Bae, J. S., Ha, H. J., & Lee, P. H. (2014). Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models. Autophagy, 10(1), 32-44.
- Zhang, L., Dong, Z. F., & Zhang, J. Y. (2020). Immunomodulatory role of mesenchymal stem cells in Alzheimer’s disease. Life sciences, 246, 117405.
- Vilaça-Faria, H., Salgado, A. J., & Teixeira, F. G. (2019). Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson’s disease?. Cells, 8(2), 118.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
